Endocannabinoids and the regulation of bone metabolism

Journal of Neuroendocrinology

Volumn 20, Issue SUPPL. 1, 2008, Pages 69-74

  Bab, Itai ^a   Ofek, O ^a   Tam, J ^a   Rehnelt, J ^b   Zimmer, A ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Bone remodelling; Endocannabinoid system; Osteoporosis; Single nucleotide polymorphism; Sympathtic nervous system

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; UNCLASSIFIED DRUG;

BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CELL ACTIVITY; CONFERENCE PAPER; DNA POLYMORPHISM; DRUG MECHANISM; GENETIC ASSOCIATION; HUMAN; METABOLIC REGULATION; NERVE CELL DIFFERENTIATION; NONHUMAN; NORADRENALIN RELEASE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY;

ANIMALS; BONE AND BONES; BRAIN; CELL DIFFERENTIATION; COMPUTER SIMULATION; ENDOCANNABINOIDS; HUMANS; MODELS, BIOLOGICAL; NEUROSECRETION; RECEPTORS, CANNABINOID;

EID: 42349086864     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01675.x     Document Type: Conference Paper

References (48)

1. Karsenty G. Genetic control of skeletal development. Novartis Found Symp 2001; 232: 6-17.
2. Gerstenfeld LC, Cullinane DM, Barnes GL, Graves DT, Einhorn TA. Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation. J Cell Biochem 2003; 88: 873-884.
3. Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 2003; 32: 25-38.
4. Donahue SW, Galley SA. Microdamage in bone: Implications for fracture, repair, remodeling, and adaptation. Crit Rev Biomed Eng 2006; 34: 215-271.
5. Lanyon LE. Using functional loading to influence bone mass and architecture: Objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Bone 1996; 18: 37S-43S.
6. Parfitt AM. Bone and plasma calcium homeostasis. Bone 1987; 8: S1-S8.
7. Roodman GD. Cell biology of the osteoclast. Exp Hematol 1999; 27: 1229-1241.
8. Ducy P, Schinke T, Karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
9. Bab IA. Regulation of skeletal remodeling by the endocannabinoid system. Ann NY Acad Sci 2007; 1116: 414-422.
10. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog h. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002; 109: 915-921.
11. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317.
12. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, Fukumoto S, Fujita T, Kato S, Kangawa K, Kojima M, Shinomiya KI, Takeda S. Central control of bone remodeling by neuromedin U. Nat Med 2007; 13: 1234-1240.
13. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus V, Shohami E, Bab I. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci USA 2006; 103: 16876-16881.
14. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-162.
15. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M. FSH directly regulates bone mass. Cell 2006; 125: 247-260.
16. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
17. Orzel JA, Rudd TG. Heterotopic bone formation: Clinical, laboratory, and imaging correlation. J Nucl Med 1985; 26: 125-132.
18. Wildburger R, Zarkovic N, Tonkovic G, Skoric T, Frech S, Hartleb M, Loncaric I, Zarkovic K. Post-traumatic hormonal disturbances: Prolactin as a link between head injury and enhanced osteogenesis. J Endocrinol Invest 1998; 21: 78-86.
19. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-531.
20. Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E, Bab I. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2007; 22: 285-294.
21. Ford L, Ridge S, Cameron G, Rogers M, Ross R. Endocannabinoids are produced by bone cells and stimulate bone resorption in vitro. Proceedings, 17th Annual Symposium of the International Cannabinoid Research Society 2007: 60.
22. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006; 45: 4720-4726.
23. Bab I. The skeleton: Stone bones and stoned heads? In: Mechoulam R ed. Cannabinoids as Therapeutics. Milestones in Drug Therapy Series. Basel: Birkhauser, 2005: 201-206.
24. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006; 103: 696-701.
25. Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, Zimmer A, Mackie K, Mechoulam R, Shohami E, Bab I. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006; 70: 786-792.
26. Scutt A, Williamson EM. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcif Tissue Int 2007; 80: 50-59.
27. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ, Ng KW. In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res 1994; 9: 1489-1499.
28. Zhang RW, Supowit SC, Xu X, Li H, Christensen MD, Lozano R, Simmons DJ. Expression of selected osteogenic markers in the fibroblast-like cells of rat marrow stroma. Calcif Tissue Int 1995; 56: 283-291.
29. Araujo AM, Buschang PH, Melo AC. Adaptive condylar growth and mandibular remodelling changes with bionator therapy-an implant study. Eur J Orthod 2004; 26: 515-522.
30. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11: 774-779.
31. Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 2005; 145: 441-448.
32. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404.
33. Amor A, Smith PA, t'Hart B, Baker D. Biozzi mice: Of mice and human neurological diseases. J Neuroimmunol 2005; 165: 1-10.
34. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780-5785.
35. Bab I, Hajbi-Yonissi C, Gabet Y, Müller R. New York, NY: Springer, 2007: 195-199.
36. Melamed E, Robinson D, Halperin N, Wallach N, Keren O, Groswasser Z. Brain injury-related heterotopic bone formation: Treatment strategy and results. Am J Phys Med Rehabil 2002; 81: 670-674.
37. Boes M, Kain M, Kakar S, Nicholls F, Cullinane D, Gerstenfeld L, Einhorn TA, Tornetta P III. Osteogenic effects of traumatic brain injury on experimental fracture-healing. J Bone Joint Surg Am 2006; 88: 738-743.
38. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96: 14228-14233.
39. George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol 2008; 214: 714-720.
40. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M. Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice. J Bone Miner Res 2001; 16: 1665-1673.
41. Karsak M, Cohen-Solal M, Freudenberg J, Ostertag A, Morieux C, Kornak U, Essig J, Erxlebe E, Bab I, Kubisch C, de Vernejoul MC, Zimmer A. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005; 14: 3389-3396.
42. McCaw E, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 2004; 271: 4909-4920.
43. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916-931.
44. Devoto M, Shimoya K, Caminis J, Ott J, Tenenhouse A, Whyte MP, Sereda L, Hall S, Considine E, Williams CJ, Tromp G, Kuivaniemi H, Ala-Kokko L, Prockop DJ, Spotila LD. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet 1998; 6: 151-157.
45. Devoto M, Specchia C, Li HH, Caminis J, Tenenhouse A, Rodriguez H, Spotila LD. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet 2001; 10: 2447-2452.
46. Devoto M, Spotila LD, Stabley DL, Wharton GN, Rydbeck H, Korkko J, Kosich R, Prockop D, Tenenhouse A, Sol-Church K. Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet 2005; 13: 781-788.
47. Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 2007; 19: 791-801.
48. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005; 30: 1216-1221.